This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Mar;17(3):e33-e34.

doi: 10.1016/j.jtho.2022.01.005.

Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"

Chengjuan Fan¹, Qiuyu Zhao¹, Chong Teng¹, Zhengjun Jiang¹, Tao Xin²

Affiliations

Affiliations

¹ Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
² Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Electronic address: xintao1234@263.net.

PMID: 35216737
DOI: 10.1016/j.jtho.2022.01.005

Free article

Comment

Response to Letter to the Editor Titled "Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases from NSCLC?"

Chengjuan Fan et al. J Thorac Oncol. 2022 Mar.

Free article

. 2022 Mar;17(3):e33-e34.

doi: 10.1016/j.jtho.2022.01.005.

Authors

Chengjuan Fan¹, Qiuyu Zhao¹, Chong Teng¹, Zhengjun Jiang¹, Tao Xin²

Affiliations

¹ Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
² Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. Electronic address: xintao1234@263.net.

PMID: 35216737
DOI: 10.1016/j.jtho.2022.01.005

No abstract available

PubMed Disclaimer

Comment on

Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T. Fan C, et al. J Thorac Oncol. 2021 Aug;16(8):1359-1368. doi: 10.1016/j.jtho.2021.04.018. Epub 2021 May 11. J Thorac Oncol. 2021. PMID: 33989780 Clinical Trial.
Focusing on Intrathecal Pemetrexed for Treating Leptomeningeal Metastases From NSCLC.
Pan Z. Pan Z. J Thorac Oncol. 2022 Mar;17(3):e31-e32. doi: 10.1016/j.jtho.2021.09.020. J Thorac Oncol. 2022. PMID: 35216736 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal